- Investing Ideas
- /
- Chinese Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Chinese Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
7
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
7 companies
Zhejiang Jolly PharmaceuticalLTD
Market Cap: CN¥12.6b
Engages in the research, production, and marketing of Chinese medicinal products in the People’s Republic of China and internationally.
300181
CN¥18.15
7D
-5.1%
1Y
12.7%
Shanghai OPM Biosciences
Market Cap: CN¥6.2b
Provides cell culture media and CDMO services in China and internationally.
688293
CN¥54.53
7D
-4.8%
1Y
64.6%
Nanjing Vazyme Biotech
Market Cap: CN¥9.0b
Offers technology solutions for life science, biomedicine, and in vitro diagnostics.
688105
CN¥22.53
7D
1.2%
1Y
-5.2%
Beijing Aosaikang Pharmaceutical
Market Cap: CN¥17.5b
Beijing Aosaikang Pharmaceutical Co., Ltd.
002755
CN¥18.87
7D
-3.1%
1Y
38.8%
MGI Tech
Market Cap: CN¥28.0b
Engages in the research, development, production, and sale of DNA sequencing instruments, reagents, and related products for precision medicine, agriculture, healthcare, and other relevant industries in China and internationally.
688114
CN¥67.85
7D
0.4%
1Y
31.1%
AcrobiosystemsLtd
Market Cap: CN¥10.1b
Engages in the development and manufacture of recombinant proteins, antibodies, and other biological reagents for pharmaceutical and biotechnology companies, and scientific research institutions.
301080
CN¥60.37
7D
5.3%
1Y
112.6%
Suzhou Highfine Biotech
Market Cap: CN¥5.4b
Manufactures and sells chemicals for pharmaceutical research and development, and API production companies in China.
301393
CN¥50.73
7D
-0.7%
1Y
10.9%